Streetbeat News

Stock Prices

IDAI

T Stamp (NASDAQ:IDAI) reported a narrower Q1 loss of $(0.26) per share compared to $(0.50) YoY, with sales increasing to $574.00K from $458.63K YoY.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:11 pm

F

LCID

RIVN

STLA

TSLA

Auto and EV stocks, including Ford (F), Lucid Motors (LCID), Rivian (RIVN), Stellantis (STLA), and Tesla (TSLA), are trading higher following President Biden's announcement of tariffs on Chinese EVs. This move is likely to benefit domestic and European manufacturers by making their vehicles more competitive against Chinese imports.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:10 pm

DVAX

The FDA declined to approve Dynavax Technologies Corporation's (DVAX) supplemental Biologics License Application for a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis, citing insufficient data. The decision does not affect the current approvals of HEPLISAV-B in the U.S., EU, and Great Britain, nor the recent approval in the EU for the hemodialysis population. Dynavax intends to meet with the FDA to discuss additional data support. Despite this, HEPLISAV-B's net product revenue increased, and its U.S. market share grew in the first quarter of 2024.

Portfolio Pulse from Vandana Singh

May 14, 2024 | 2:10 pm

POET

POET Technologies Inc. (NASDAQ:POET) has been selected by Foxconn Interconnect Technology to supply silicon photonics integrated circuits (Silicon PIC) for 800G and 1.6T optical transceiver modules. This partnership aims to serve advanced AI and high-speed data center networks. POET will provide optical engines using its Optical Interposer technology, contributing to a market expected to grow at a 33% CAGR, reaching $10.5 billion by 2029. The design completion for these optical engines is anticipated by Q3 2024, with production starting in Q4 2024 at Super Photonics Xiamen, a joint venture. POET's stock saw a 9.59% increase to $2.38.

Portfolio Pulse from Akanksha Bakshi

May 14, 2024 | 2:06 pm

KURA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Kura Oncology (NASDAQ:KURA) with a maintained price target of $32.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:02 pm

FDCF

FMQQ

SE

Sea Limited (NYSE:SE) reported a 22.8% year-on-year revenue growth for Q1 2024, surpassing analyst estimates with $3.73 billion. Despite this, EPS saw a decline, missing expectations. The company's digital entertainment segment experienced a revenue decrease, while e-commerce and digital financial services saw significant growth. Sea Limited's CEO, Forrest Li, expressed optimism about the company's growth and profitability roadmap for 2024. SE shares rose by 7% in premarket trading but later dropped by 1.29%. The stock can also be accessed through FMQQ and FDCF ETFs.

Portfolio Pulse from Anusuya Lahiri

May 14, 2024 | 2:02 pm

OWL

Blue Owl Cap (NYSE:OWL) received diverse analyst ratings over the last three months, with a total of 9 evaluations ranging from bullish to bearish. The average 12-month price target for OWL is now $21.72, up 7.68% from the previous $20.17, with a high estimate of $24.00 and a low of $19.00. Analyst actions include ratings adjustments and price target changes, reflecting dynamic market conditions and company performance. Blue Owl Capital, an alternative asset management firm, shows a positive revenue trend with a 31.29% growth rate as of March 31, 2024, but faces challenges in net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 2:01 pm

WFRD

Analyst ratings for Weatherford International (NASDAQ:WFRD) show a mix of bullish sentiments with an average 12-month price target of $155.17, reflecting a 13.89% increase from the previous target. Recent actions by analysts include upgrades and maintenance of buy and overweight ratings, indicating positive expectations for WFRD's performance.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 2:01 pm

VRTX

Vertex Pharmaceuticals (NASDAQ:VRTX) has significantly outperformed the market with an average annual return of 20.63% over the past 10 years, turning a $100 investment into $635.73 today. The company's market capitalization stands at $110.28 billion.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 2:00 pm

MMC

Marsh & McLennan (NYSE:MMC) has delivered an average annual return of 16.39% over the past 5 years, outperforming the market by 3.45% on an annualized basis. With a current market capitalization of $100.91 billion, an initial investment of $1000 in MMC stock 5 years ago would be worth $2,138.01 today.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 2:00 pm